Mohs surgery is typically qualified for skin cancers in high-risk locations, cancers with aggressive growth patterns, tumors that have come back after previous treatment, and large or poorly defined tumors where preserving healthy tissue matters. The procedure isn’t used for every skin cancer. A combination of factors, including where the tumor sits on your body, what it looks like under the microscope, and your overall health, determines whether Mohs is the right approach.
Why Mohs Is Different From Standard Removal
The core advantage of Mohs surgery is precision. During standard excision, the removed tissue is sliced vertically (like a loaf of bread) and examined, but this method evaluates less than 2% of the surgical margin. Mohs takes a fundamentally different approach: tissue is sliced horizontally in thin layers, allowing the surgeon to examine 100% of the margin under a microscope while you wait. If cancer cells remain at any edge, the surgeon removes another layer from that exact spot and checks again.
This layer-by-layer process means two things. First, cure rates are high: five-year recurrence rates for primary skin cancers treated with Mohs run around 2.5% to 4.1%, compared with higher rates for standard excision. Second, the surgeon removes only what’s necessary, sparing as much healthy skin as possible. That tissue-sparing quality is what makes Mohs especially valuable in sensitive areas where every millimeter of skin matters.
Location on the Body
Tumor location is one of the strongest factors in qualifying for Mohs. Clinical guidelines divide the body into risk zones, with the highest-risk zone (called Area H) covering the “mask areas” of the face: the central face, eyelids, eyebrows, the skin around the eyes, nose, lips, chin, jawline, temples, ears, and the skin in front of and behind the ears. Genitalia, hands, and feet are also classified as Area H.
These areas qualify because they share two characteristics. The skin is functionally or cosmetically important, so removing extra tissue as a safety margin carries real consequences. And many of these sites, particularly the nose, ears, and eye area, have complex underlying anatomy where tumors can extend along tissue planes in unpredictable directions. A cancer on the tip of your nose, for example, almost always qualifies for Mohs, while the same cancer type and size on your back likely would not.
Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common reason people have Mohs surgery. Not every BCC qualifies, though. The decision depends on the subtype. BCCs that grow in aggressive patterns, such as those with infiltrative, morpheaform (scar-like), or micronodular features, are strong candidates because they send irregular projections into surrounding tissue that standard excision can miss.
Even BCCs that appear non-aggressive on biopsy can harbor surprises. A study of 825 BCCs found that 28% of tumors initially classified as non-aggressive on biopsy turned out to have aggressive subtypes once the Mohs surgeon examined the full specimen. These hidden aggressive BCCs required more surgical stages to clear (an average of 2.37 stages versus 1.50 for truly non-aggressive tumors). The risk of this mismatch was highest for nodular BCCs and for tumors in Area H, where a biopsy is 2.65 times more likely to underrepresent aggressive features compared to tumors on the trunk or extremities.
Large BCCs, those with poorly defined borders, and BCCs growing near critical structures like the eye or ear canal also commonly qualify regardless of subtype.
Squamous Cell Carcinoma
Squamous cell carcinoma (SCC) qualifies for Mohs when it carries high-risk features. The most important markers include a tumor diameter of 2 cm or larger, invasion into deeper tissue layers, involvement of nerves (which you might notice as numbness or tingling near the tumor), and location in Area H. SCCs that developed in areas of prior radiation or chronic scarring also qualify.
Tumor size plays a particularly well-studied role. Tumors 2 cm or larger at clinical measurement carry higher risks of recurrence and lymph node spread. Research on 517 SCCs treated with Mohs found that this size threshold holds whether measured before surgery or after removal, confirming it as a reliable cutoff for identifying high-risk tumors that benefit from the precision of margin-checked surgery.
Recurrent and Incompletely Removed Cancers
Any skin cancer that has come back after previous treatment is a strong candidate for Mohs. Recurrent tumors are harder to treat because scar tissue from the first procedure obscures their borders, making it difficult to tell where cancer ends and normal tissue begins. Five-year recurrence rates for previously treated tumors run between 2.4% and 12.1% depending on the method used, compared with lower rates for tumors treated the first time around. Mohs gives the surgeon real-time microscopic confirmation of clear margins, which is especially valuable when scar tissue is in the mix.
Similarly, if a standard excision comes back with positive margins (meaning cancer cells were found at the edge of the removed tissue), Mohs is frequently the recommended next step rather than simply cutting wider.
Rare Tumor Types
Mohs isn’t limited to the two most common skin cancers. Dermatofibrosarcoma protuberans (DFSP), a rare soft-tissue tumor that tends to send finger-like extensions far beyond its visible borders, is considered appropriate for Mohs in all body locations and all patient types. Standard excision of DFSP typically requires very wide margins of 2 to 3 cm, which Mohs can often reduce significantly while still achieving clear margins.
Other less common skin cancers that may qualify include certain sweat gland tumors, sebaceous carcinomas, and other tumors that grow in a contiguous (connected) pattern, since the layer-by-layer approach can track their edges effectively.
Patient-Specific Risk Factors
Your individual health profile can tip the scales toward Mohs even when the tumor itself might otherwise be treated with standard excision. Immunosuppression is the most significant patient factor. If you’ve had an organ transplant, are taking immunosuppressive medications, have a blood cancer like chronic lymphocytic leukemia, or are HIV-positive, your skin cancers tend to behave more aggressively and recur at higher rates. Mohs is considered the preferred treatment for high-risk skin cancers in immunosuppressed patients because of its superior margin control.
Genetic conditions that predispose you to multiple skin cancers, such as basal cell nevus syndrome or xeroderma pigmentosum, also weigh in favor of Mohs. When you’re likely to develop many skin cancers over a lifetime, the tissue-sparing nature of Mohs helps preserve as much healthy skin as possible for future procedures. A history of radiation therapy to the area where the cancer appeared is another qualifying factor, since radiation-damaged skin tends to produce more aggressive tumors with less predictable borders.
How the Decision Gets Made
Qualification for Mohs isn’t a single yes-or-no checkbox. Dermatologists use published Appropriate Use Criteria that rate hundreds of clinical scenarios based on the combination of tumor type, location, size, growth pattern, patient immune status, and whether the cancer is new or recurrent. Each scenario receives a rating of “appropriate,” “uncertain,” or “inappropriate.”
In practice, the clearest qualifications combine multiple risk factors: a morpheaform BCC on the nose of a transplant patient, for instance, would be rated appropriate by virtually any standard. A small, well-defined nodular BCC on the trunk of a healthy person would not. Many real-world cases fall somewhere in between, and your dermatologist weighs the full picture.
Mohs surgeons complete specialized fellowship training beyond dermatology residency, accredited through the ACGME or recognized by the American College of Mohs Surgery. This training covers not just the surgical technique but also the microscopic interpretation and the reconstructive repair that typically follows in the same visit. If your dermatologist recommends Mohs, the referral will go to a fellowship-trained Mohs surgeon who handles the entire procedure, from removal through reconstruction, in a single appointment.